EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting the MHC-I endosomal-lysosomal trafficking pathway in cancer: From mechanism to immunotherapy

Di Ye, Shuang Zhou, Xinyu Dai, Huanji Xu, Qiulin Tang, Huixi Huang, Feng Bi

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2024

DOI: 10.1016/j.bbcan.2024.189161 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2024. Verfasst von Di Ye und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Abdominal Cancer, Department of Medical Oncology, Cancer Center and Laboratory of Molecular Targeted Therapy in Oncology, West China Hosp…. Hauptthemen laut MEDLINE: Neoplasms, Lysosomes, Endosomes, Histocompatibility Antigens Class I. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 144 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint blockade (ICB) therapy has achieved broad applicability and durable clinical responses across cancer types. However, the overall response rate remains suboptimal because some patients do not respond or develop drug resistance. The low infiltration of CD8+ cytotoxic T cells (CTLs) in the tumor microenvironment due to insufficient antigen presentation is closely related to the innate resistance to ICB. The duration and spatial distribution of major histocompatibility complex class I (MHC-I) expression on the cell surface is critical for the efficient presentation of endogenous tumor antigens and subsequent recognition and clearance by CTLs. Tumor cells reduce the surface expression of MHC-I via multiple mechanisms to impair antigen presentation pathways and evade immunity and/or develop resistance to ICB therapy. As an increasing number of studies have focused on membrane MHC-I trafficking and degradation in tumor cells, which may impact the effectiveness of tumor immunotherapy. It is necessary to summarize the mechanism regulating membrane MHC-I translocation into the cytoplasm and degradation via the lysosome. We reviewed recent advances in the understanding of endosomal-lysosomal MHC-I transport and highlighted the means exploited by tumor cells to evade detection and clearance by CTLs. We also summarized new therapeutic strategies targeting these pathways to enhance classical ICB treatment and provide new avenues for optimizing cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsLysosomesEndosomesHistocompatibility Antigens Class IImmunotherapyHumansAnimalsProtein TransportTumor MicroenvironmentAntigen PresentationImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

CD8(+) cytotoxic T cellsEndosomal-lysosomal traffickingImmune checkpoint blockadeImmune evasionMajor histocompatibility complex class I

Substanzen

Histocompatibility Antigens Class IImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Division of Abdominal Cancer, Department of Medical Oncology, Cancer Center and Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, China.
  • Division of Abdominal Cancer, Department of Medical Oncology, Cancer Center and Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, China. Ele…

Zitieren

APA

Ye, D., Zhou, S., Dai, X., Xu, H., Tang, Q., Huang, H., & Bi, F. (2024). Targeting the MHC-I endosomal-lysosomal trafficking pathway in cancer: From mechanism to immunotherapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2024.189161

Vancouver

Ye D, Zhou S, Dai X, Xu H, Tang Q, Huang H, et al. Targeting the MHC-I endosomal-lysosomal trafficking pathway in cancer: From mechanism to immunotherapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2024. doi:10.1016/j.bbcan.2024.189161

BibTeX
@article{Ye2024,
  author = {Ye, Di and Zhou, Shuang and Dai, Xinyu and Xu, Huanji and Tang, Qiulin and Huang, Huixi and Bi, Feng},
  title = {Targeting the MHC-I endosomal-lysosomal trafficking pathway in cancer: From mechanism to immunotherapy},
  journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
  year = {2024},
  doi = {10.1016/j.bbcan.2024.189161}
}
Kostenlos starten →